New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
12:00 EDTCYTKCytokinetics falls 62%
Cytokinetics is down 62%, or $8.05, to $4.94
News For CYTK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
16:19 EDTCYTKCytokinetics sees initiating phase 3 tirasemtiv program in Q2
Cytokinetics (CYTK) expects to initiate a phase III clinical development program for tirasemtiv in patients with ALS in Q2. Cytokinetics expects to initiate a phase II trial of CK-2127107 in patients with SMA in 2H. Cytokinetics expects results from COSMIC-HF to be available in 2H. Cytokinetics expects to continue joint development activities in collaboration with Amgen (AMGN) directed to the potential advancement of omecamtiv mecarbil to phase III clinical development.
16:17 EDTCYTKCytokinetics reports Q1 EPS (23c), may not compare to consensus (12c)
Reports Q1 revenue $4.41M, may not compare to consensus $10.08M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use